NCIC CTG IND.122: a phase I/II pharmacokinetics (PK) and pharmacodynamic (PD) study of zd1839 (iressa ‘TM’). Final phase I results and preliminary phase II results of ZD1839 (750 mg/day) in patients (pts) with colorectal cancer
- 30 April 2001
- journal article
- abstracts
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 37, S289
- https://doi.org/10.1016/s0959-8049(01)81559-8